2014 Fiscal Year Final Research Report
Purinergic signaling is a novel target of sepsis therapy
| Project/Area Number |
24590125
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Tokyo University of Science |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | 敗血症 / 炎症 / プリン受容体 / P2X7受容体 / P2Y11受容体 / ATP / サイトカイン / マクロファージ |
|---|
| Outline of Final Research Achievements |
Sepsis is known as systemic inflammatory response syndorome (SIRS) with symptoms such as hypercytokinemi. Now, it is need to improve the therapy of sepsis. To establish effective therapy of sepsis, we investigated a role of purinergic signaling on sepsis by using immune cells and sepsis model mice in this study. We found that activation of P2Y11 receptor by exocytic ATP release in macrophage is involved in production of pro-inflammatory cytokine. P2Y11 receptor antagonist suppressed an increase of cytokine in LPS-treated mice. On the other hand, we also found that activation of P2X7 receptor play an important role in sepsis, suggesting that P2Y11 and P2X7 receptor antagonists would become a novel candidate of sepsis therapy.
|
| Free Research Field |
生物系薬学
|
